- 2024 year
- 2023 year
- 2022 year
- 2021 year
- 2020 year
- 2019 year
- 2018 year
- 2017 year
- 2016 year
- 2015 year
- 2014 year
- 2013 year
- 2012 year
Health is the lack of internal interference for life
Contacts
"InterChem" opens new horizons
Pharmaceutical company "InterChemm" took part in the largest pharmaceutical exhibition in East Africa - Africa Pharmaceutical Summit East 2016, which took place in Kenya this February.
General Director of the Company Anatoly Reder managed to productively communicate with the leadership of the registration service in Kenya. "They are qualified professionals who are very interested in Ukrainian manufacturers on the local pharmaceutical market. Considering Ukraine as part of Europe, they are hoping that the product that we can deliver, will be high quality, meet all European requirements, but will be less expensive than European counterparts."
Anatoly Reder said that the pharmaceutical market in Kenya is relatively weak and difficult because of the distribution routes. According to preliminary estimates, its volume is about $250 million per year. While the country's population is comparable to Ukrainian`s. Also about $450 million of donor funding is used up in the fight against malaria and HIV. Products sold in Kenya, is low-margin. This means that business is difficult. Nevertheless, the market is growing, and many processes are very close and clear to Ukraine.
As a result of participation in the exhibition "InterChem" decided to take up the question of entering the African pharmaceutical market. The registration procedure for importers in East Africa as well as in Europe implies the need to prove the bioequivalence of the drug, which requires additional investment and time expenses. Bioequivalence study process is complicated by the fact that today in Ukraine there are only 3-4 laboratories that can do such a study, which can carry out maximum of two studies per year. Of course, in the world is enough of such laboratories, however, conducting research abroad, promotes the outflow of capital from the country. Therefore, Ukraine needs to focus on how to appear more domestic laboratories of such profile, as in many countries of the world bioequivalence - is a major barrier for registration.
Anatoly Reder also shared plans "Interchimie" for the future: "We are developing three new molecules. Now the next stage of preclinical studies of the drug from a sore throat. Also we are working on nootropic drug that will restore the memory - the results of preclinical studies are very encouraging. "
General Director of the Company Anatoly Reder managed to productively communicate with the leadership of the registration service in Kenya. "They are qualified professionals who are very interested in Ukrainian manufacturers on the local pharmaceutical market. Considering Ukraine as part of Europe, they are hoping that the product that we can deliver, will be high quality, meet all European requirements, but will be less expensive than European counterparts."
Anatoly Reder said that the pharmaceutical market in Kenya is relatively weak and difficult because of the distribution routes. According to preliminary estimates, its volume is about $250 million per year. While the country's population is comparable to Ukrainian`s. Also about $450 million of donor funding is used up in the fight against malaria and HIV. Products sold in Kenya, is low-margin. This means that business is difficult. Nevertheless, the market is growing, and many processes are very close and clear to Ukraine.
As a result of participation in the exhibition "InterChem" decided to take up the question of entering the African pharmaceutical market. The registration procedure for importers in East Africa as well as in Europe implies the need to prove the bioequivalence of the drug, which requires additional investment and time expenses. Bioequivalence study process is complicated by the fact that today in Ukraine there are only 3-4 laboratories that can do such a study, which can carry out maximum of two studies per year. Of course, in the world is enough of such laboratories, however, conducting research abroad, promotes the outflow of capital from the country. Therefore, Ukraine needs to focus on how to appear more domestic laboratories of such profile, as in many countries of the world bioequivalence - is a major barrier for registration.
Anatoly Reder also shared plans "Interchimie" for the future: "We are developing three new molecules. Now the next stage of preclinical studies of the drug from a sore throat. Also we are working on nootropic drug that will restore the memory - the results of preclinical studies are very encouraging. "